Skip to main content
SpringerLink
Log in

Do antiphospholipid antibodies develop for a purpose?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

There is a growing body of literature suggesting that antiphospholipid antibodies develop for a purpose, that they play several key roles in the innate immune response, and are only rendered pathologic in susceptible people under adverse intravascular conditions. This paper will review evidence that the autoantibodies associated with the antiphospholipid syndrome develop from natural autoantibodies for purposes that are beneficial to host defense, and are only rendered pathologic as a result of adverse intravascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Czompoly T, Olasz K, Simon D, et al.: A possible new bridge between innate and adaptive immunity: Are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network? Mol Immunol 2005, In press.

  2. Baumgarth N, Tung JW, Herzenberg LA: Inherent speci-.cities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005, 26:347–362. s review article summarizes current understanding of natural autoantibodies and their role in immune defense.

    Article  PubMed  CAS  Google Scholar 

  3. Chang MK, Boullier A, Hartvigsen K, et al.: The role of natural antibodies in atherogenesis. J Lipid Res 2005, 46:1353–1363. s paper suggests that natural autoantibodies might have complicated effects in the bloodstream, including a role in the pathogenesis of atherosclerosis.

    Article  PubMed  CAS  Google Scholar 

  4. Binder CJ, Silverman GJ: Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 2005, 26:385–404.

    Article  PubMed  CAS  Google Scholar 

  5. Zohar Y, Wildbaum G, Karin N: Beneficial autoimmunity participates in the regulation of rheumatoid arthritis. Front Biosci 2006, 11:368–379.

    Article  PubMed  CAS  Google Scholar 

  6. McIntyre JA, Wagenknecht DR, Faulk WP: Redox-reactive autoantibodies: Detection and physiological relevance. Autoimmun Rev 2006, 5:76–83.

    Article  PubMed  CAS  Google Scholar 

  7. McIntyre JA: The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation- reduction reactions. Thromb Res 2004, 114:579–587. s paper elucidates some of the problems in the detection and understanding of antiphospholipid antibodies and provides data consistent with the hypothesis that they have binding characteristics in common with natural autoantibodies.

    Article  PubMed  CAS  Google Scholar 

  8. Blank M, Asherson RA, Cervera R, Shoenfeld Y: Antiphospholipid syndrome infectious origin. J Clin Immunol 2004, 24:12–23. This paper contains important concepts in the understanding of how antiphospholipid antibodies might evolve from key host defense against infection.

    Article  PubMed  CAS  Google Scholar 

  9. Shovman O, Gilburd B, Barzilai O, et al.: Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 2005, 1050:380–388.

    Article  PubMed  CAS  Google Scholar 

  10. Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O: Prevalence of positive antinuclear antibodies in healthy children. Asian Pac J Allergy Immunol 2005, 23:153–157.

    PubMed  Google Scholar 

  11. Fields RA, Toubbeh H, Searles RP, Bankhurst AD: The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989, 16:623–625.

    PubMed  CAS  Google Scholar 

  12. Shi W, Krilis SA, Chong BH, et al.: Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990, 20:231–236.

    PubMed  CAS  Google Scholar 

  13. McIntyre JA, Wagenknecht DR, Faulk WP: Autoantibodies unmasked by redox reactions. J Autoimmun 2005, 24:311–317.

    Article  PubMed  CAS  Google Scholar 

  14. Stahl D, Hoemberg M, Cassens U, et al.: Influence of isotypes of disease-associated autoantibodies on the expression of natural autoantibody repertoires in humans. Immunol Lett 2006, 102:50–59.

    Article  PubMed  CAS  Google Scholar 

  15. Reipert BM, Tanneberger S, Pannetta A, et al.: Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother 2005, 54:1038–1042.

    Article  PubMed  CAS  Google Scholar 

  16. Yuste JR, Prieto J: Anticardiolipin antibodies in chronic viral hepatitis. Do they have clinical consequences? Eur J Gastroenterol Hepatol 2003, 15:717–726.

    Article  PubMed  CAS  Google Scholar 

  17. Asherson RA, Cervera R: Antiphospholipid antibodies and infections. Ann Rheum Dis 2003, 62:388–393.

    Article  PubMed  CAS  Google Scholar 

  18. Lee J, Cho YJ, Lipsky PE: The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire. Arthritis Rheum 2004, 50:2604–2614. This paper supports the hypothesis that pathologic autoantibodies might derive from an innate immune response that was originally in the interests of the host.

    Article  PubMed  CAS  Google Scholar 

  19. Quintana FJ, Cohen IR: The natural autoantibody repertoire and autoimmune disease. Biomed Pharmacother 2004, 58:276–281.

    Article  PubMed  CAS  Google Scholar 

  20. Djoumerska I, Tchorbanov A, Pashov A, Vassilev T: The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand J Immunol 2005, 61:357–363.

    Article  PubMed  CAS  Google Scholar 

  21. Lieby P, Poindron V, Roussi S, et al.: Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 2004, 104:1711–1715.

    Article  PubMed  CAS  Google Scholar 

  22. Field SL, Brighton TA, McNeil HP, Chesterman CN: Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:407–422.

    Article  PubMed  CAS  Google Scholar 

  23. Rauch J, Subang R, D’Agnillo P, et al.: Apoptosis and the antiphospholipid syndrome. J Autoimmun 2000, 15:231–235.

    Article  PubMed  CAS  Google Scholar 

  24. Languren M, Becerril B, Cabral AR, et al.: Characterization of monoclonal anti-beta(2)-glycoprotein-I and antiprothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. J Autoimmun 2006, 26:57–65.

    Article  PubMed  CAS  Google Scholar 

  25. Rauch J, D’Agnillo P, Subang R, Levine JS: Antiphospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid- dependent interactions with apoptotic cells. Thromb Res 2004, 114:371–382.

    Article  PubMed  CAS  Google Scholar 

  26. Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169–174.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 825 NE 13th Street, 73104, Oklahoma City, OK, USA

    Joan T. Merrill MD

Authors
  1. Joan T. Merrill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan T. Merrill MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merrill, J.T. Do antiphospholipid antibodies develop for a purpose?. Curr Rheumatol Rep 8, 109–113 (2006). https://doi.org/10.1007/s11926-006-0050-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0050-2

Keywords

Search

Navigation